Category
Biologics & Advanced Therapies
Modern targeted treatments for moderate-severe IBD
Entyvio vs Stelara for Ulcerative Colitis: Which to Choose?
Entyvio and Stelara are two of the most common biologics used for ulcerative colitis after a patient has failed an anti-TNF, and they are increasingly considered first-line options as well. Both avoid the systemic TNF blockade that raises infection risk in anti-TNF therapy, but they do so through very different mechanisms. Entyvio is gut-selective. Stelara blocks an upstream cytokine pathway that affects inflammation throughout the body. For UC patients weighing a second-line biologic or looking for a safer first-line option, the decision often hinges on onset of action, efficacy in anti-TNF experienced patients, and dosing convenience. This guide walks through the evidence UC patients need to make an informed entyvio vs stelara ulcerative colitis decision.
Entyvio vs Stelara for Crohn's Disease: Which Is Better?
Entyvio and Stelara are two of the most common biologics prescribed when an anti-TNF like Humira or Remicade stops working for Crohn's disease. Both are alternatives to TNF blockade, but they take very different mechanistic paths to quiet gut inflammation. Entyvio is gut-selective. Stelara targets a cytokine pathway that operates throughout the body but is especially active in the gut. For patients weighing a second-line choice, the decision often hinges on infection risk, onset of action, and long-term safety. This guide walks through the evidence patients need to make an informed entyvio vs stelara crohn's decision with their gastroenterologist.
Entyvio vs Remicade for Ulcerative Colitis: Comparing Biologics
Entyvio and Remicade are the two most commonly used intravenous biologics for ulcerative colitis. Remicade is a broad anti-tumor necrosis factor agent with decades of real-world data. Entyvio is a gut-selective biologic that acts almost exclusively on the intestines. For UC patients who want infusion-based therapy but are weighing targeted vs systemic action, this is a common comparison. This guide walks through the evidence on entyvio vs remicade ulcerative colitis across mechanism, efficacy, safety, and practical considerations.
Entyvio vs Humira for Ulcerative Colitis: Head-to-Head
Entyvio and Humira are two of the most commonly prescribed biologics for ulcerative colitis, and they represent very different approaches to quieting inflammation. Humira is a systemic anti-TNF that affects immune signaling throughout the body. Entyvio is gut-selective and acts almost exclusively in the intestines. Uniquely for biologic comparisons in UC, there is direct head-to-head randomized trial data. The VARSITY trial compared these two drugs directly, and the results have meaningfully shaped how gastroenterologists think about first-line biologic choice in UC. This guide walks through the evidence patients need to make an informed entyvio vs humira ulcerative colitis decision.
Cimzia vs Tremfya for Crohn's Disease: A Patient Guide
Cimzia and Tremfya represent two very different generations of biologic therapy for moderate-to-severe Crohn's disease. Cimzia (certolizumab pegol) is a subcutaneous anti-TNF biologic that has been a Crohn's option since 2008. Tremfya (guselkumab) is an IL-23 p19-selective biologic that gained Crohn's approval in March 2025 based on GALAXI-2, GALAXI-3, and GRAVITI. Patients comparing these drugs weigh established anti-TNF mechanism against a newer IL-23 class with distinctive induction flexibility. This guide walks through the cimzia vs tremfya crohn's comparison.
Cimzia vs Stelara for Crohn's Disease: How They Compare
Cimzia and Stelara are two subcutaneous biologics for moderate-to-severe Crohn's disease that work through fundamentally different mechanisms. Cimzia (certolizumab pegol) is an anti-TNF biologic. Stelara (ustekinumab) is an IL-12/23 inhibitor. Patients comparing these drugs often weigh established TNF-alpha blockade against the IL-12/23 pathway, particularly when considering first-line therapy or switching after anti-TNF failure. This guide walks through the cimzia vs stelara crohn's decision.
Cimzia vs Skyrizi for Crohn's Disease: Comparing Options
Cimzia and Skyrizi represent two different generations of biologic therapy for moderate-to-severe Crohn's disease. Cimzia (certolizumab pegol) is a subcutaneous anti-TNF biologic that has been a Crohn's option since 2008. Skyrizi (risankizumab) is an IL-23 p19-selective biologic approved for Crohn's in June 2022 based on the ADVANCE, MOTIVATE, and FORTIFY trials. Patients comparing these drugs weigh established anti-TNF mechanism against a newer class with strong efficacy and safety data. This guide walks through the cimzia vs skyrizi crohn's comparison.
Cimzia vs Remicade for Crohn's Disease: Key Differences
Cimzia and Remicade are two anti-TNF biologics for moderate-to-severe Crohn's disease, but they take different administration routes. Cimzia (certolizumab pegol) is a subcutaneous injection. Remicade (infliximab) is an intravenous infusion. Both block TNF-alpha, but the administration difference and Cimzia's unique Fab structure shape the practical comparison. This guide walks through the cimzia vs remicade crohn's decision.
Cimzia vs Omvoh for Crohn's Disease: Which Is Better?
Cimzia and Omvoh represent two very different generations of biologic therapy for moderate-to-severe Crohn's disease. Cimzia (certolizumab pegol) is a subcutaneous anti-TNF biologic that has been a Crohn's option since 2008. Omvoh (mirikizumab) is a newer IL-23 p19-selective biologic that gained Crohn's approval in January 2025 based on VIVID-1. Patients comparing these drugs weigh established anti-TNF mechanism against a newer IL-23 class. This guide walks through the cimzia vs omvoh crohn's comparison.
Cimzia vs Humira for Crohn's Disease: Comparing Anti-TNFs
Cimzia and Humira are two subcutaneous anti-TNF biologics for moderate-to-severe Crohn's disease. Both block TNF-alpha, but they differ in molecular structure in ways that can matter for specific patient populations, particularly those considering pregnancy. Cimzia (certolizumab pegol) is a PEGylated antibody fragment without an Fc region, while Humira (adalimumab) is a full IgG antibody. This guide walks through the cimzia vs humira crohn's comparison.
Cimzia vs Entyvio for Crohn's Disease: A Comparison
Cimzia and Entyvio take very different mechanistic approaches to moderate-to-severe Crohn's disease. Cimzia (certolizumab pegol) is a subcutaneous anti-TNF biologic. Entyvio (vedolizumab) is a gut-selective biologic. Patients comparing these drugs often weigh a systemic anti-TNF approach against a gut-targeted strategy with a favorable systemic safety profile. This guide walks through the cimzia vs entyvio crohn's comparison.
Stelara vs Remicade for Crohn's Disease: Comparing Biologics
Stelara vs Remicade for Crohn's: mechanism, healing, safety, and dosing compared.